Customize Your Learning Experience!

Mix-and-match sessions from these additional co-located conferences at no additional cost:

• Antibody Development & Production
• Recombinant Protein & Complex Biologic Development & Production
• Biobetters & Biosimilars: Technologies & Development Strategies

Arrive early so you can attend the first half of the week, Feb. 27-28 for these conferences:

• Process & Product Validation
• Technology Transfer for Biopharmaceuticals
• Outsourcing Manufacturing of Biopharmaceuticals
• Biopharmaceutical Raw Materials throughout the Product Lifecycle
• Viral Safety for Biologicals

Get the Most Out of Your Budget with the "All Access Pass" to Attend Sessions from All 9 Conferences

View the Agenda-At-A-Glance for the Entire Week.

Special Discounted Hotel Rate

Special Discounted Hotel Rate Available Until February 3, 2012.
To book your room, call 1-800-HILTONS and mention that you are an IBC attendee at this event.

Request Your 2012 Event Updates

Join the priority contact list today!

See Who Attended in 2011

Read a sample of who attended the conference in 2011.
Updated: March 16, 2011

Companies are constantly challenged with developing new tools to better understand, monitor and control their processes to ensure product quality, which makes it so critical to choose the proper analytical tools they need to incorporate at all stages of process/product development. The Analytical Technologies for Biotherapeutic Development conference offers you the unique opportunity to hear how your peers are successfully developing and integrating the latest analytical technologies to optimize quality at every stage of process and product development.

This Conference Will Help You:

• Learn how companies are developing and implementing the analytics of the future and their impact on bioprocessing
• Evaluate the powerful tools, characterization strategies and emerging techniques that can optimize process and product quality

Covering these Critical Topics:

• Successful strategies to interface analytics with process development and formulations
• Advances in high-throughput analytics, data analysis and electronic data handling
• Improving process related impurity analysis for host cell proteins, extractables and leachables
• Identifying and controlling critical quality attributes
• Analytical approaches to overcome the challenges of developing novel and enhanced molecules
• Impact of process changes and influence of trace elements on protein glycosylation
• Benefits gained from applying QbD to demonstrate comparability and biosimilarity
• Approaches to optimize biophysical characterization methods for high concentration formulations

Keynote Presentations:

Comparability and Biosimilarity -Two Sides of the Same (or a Different) Coin?
Drew N. Kelner, Ph.D.
Amgen Inc.

Is Innovation Dead in a Platform World?
Thomas Spitznagel, Ph.D.
Human Genome Sciences

The CHO Cell Factory: Engineering the Shift from Screening to Design
David C. James, Ph.D.
University of Sheffield, United Kingdom

MMV Contamination: A Case Study and, Lessons for the Industry
Mark D. Moody, Ph.D.
Merrimack Pharmaceuticals

Special thanks to the Scientific Advisory Committee for their help in developing this program.
» View the list of committee members